Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma

MLA

Karolina Piechna, et al. “Activity and Rational Combinations of a Novel, Engineered Chimeric, TRAIL-Based Ligand in Diffuse Large B-Cell Lymphoma.” Frontiers in Oncology, vol. 12, Oct. 2022. EBSCOhost, https://doi.org/10.3389/fonc.2022.1048741.

APA

Karolina Piechna, Aleksandra Żołyniak, Ewa Jabłońska, Monika Noyszewska-Kania, Maciej Szydłowski, Bartłomiej Żerek, Maria Kulecka, Izabela Rumieńczyk, Michał Mikula, & Przemysław Juszczyński. (2022). Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1048741

Chicago

Karolina Piechna, Aleksandra Żołyniak, Ewa Jabłońska, Monika Noyszewska-Kania, Maciej Szydłowski, Bartłomiej Żerek, Maria Kulecka, Izabela Rumieńczyk, Michał Mikula, and Przemysław Juszczyński. 2022. “Activity and Rational Combinations of a Novel, Engineered Chimeric, TRAIL-Based Ligand in Diffuse Large B-Cell Lymphoma.” Frontiers in Oncology 12 (October). doi:10.3389/fonc.2022.1048741.